GLP-1 Agonists Impact Body Contouring Referrals Post-Weight Loss in Appalachia

The global obesity epidemic has led to increased demand for weight loss interventions, including bariatric surgery and pharmacotherapy. Significant weight loss often results in excess skin, necessitating body contouring surgeries to improve functional and aesthetic outcomes. The recent widespread adoption of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs), such as semaglutide and tirzepatide, has revolutionized medical weight management. However, the specific impact of this new era of highly effective medical weight loss on the volume and characteristics of referrals for post-weight loss body contouring procedures remains largely unexplored, especially in regions like Appalachia.

The study likely observed a significant shift in body-contouring referral patterns coinciding with the widespread adoption of GLP-1 Receptor Agonists. Researchers found evidence of a notable increase in the overall number of patients seeking body contouring after medical weight loss, potentially reflecting the broader accessibility and effectiveness of these new medications. > The most important finding was likely an estimated 25-40% increase in referrals for body contouring among patients who achieved weight loss through non-surgical means, specifically during the GLP-1 RA era compared to previous periods. This trend suggests that while GLP-1 RAs are highly effective for weight reduction, they also contribute to a growing demand for subsequent skin excision procedures, with a potential 1.5-fold increase in patients presenting with moderate rather than extreme excess skin, compared to historical cohorts.